Colleen F. Reitan's most recent trade in Myriad Genetics, Inc. was a trade of 49,796 Common Stock done . Disclosure was reported to the exchange on June 5, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Myriad Genetics, Inc. | Colleen F. Reitan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 49,796 | 92,329 (0%) | 0% | 0 | Common Stock | |
| Myriad Genetics, Inc. | Colleen F. Reitan | Director | Sale of securities on an exchange or to another person at price $ 27.95 per share. | 03 Sep 2024 | 46,012 | 42,533 (0%) | 0% | 27.9 | 1,285,851 | Common Stock |
| Alnylam Pharmaceuticals Inc | Colleen F. Reitan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Aug 2024 | 1,558 | 1,558 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Colleen F. Reitan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Aug 2024 | 775 | 775 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Colleen F. Reitan | Director | Sale of securities on an exchange or to another person at price $ 232.86 per share. | 29 Aug 2024 | 36 | 0 (0%) | 0% | 232.9 | 8,383 | Common Stock |
| Alnylam Pharmaceuticals Inc | Colleen F. Reitan | Director | Purchase of securities on an exchange or from another person at price $ 286.00 per share. | 29 Aug 2024 | 32 | 32 (0%) | 0% | 286 | 9,152 | Common Stock |
| Alnylam Pharmaceuticals Inc | Colleen F. Reitan | Director | Purchase of securities on an exchange or from another person at price $ 302.75 per share. | 29 Aug 2024 | 4 | 36 (0%) | 0% | 302.8 | 1,211 | Common Stock |
| Myriad Genetics, Inc. | Colleen F. Reitan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 15,695 | 88,545 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Colleen F. Reitan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 5,228 | 5,228 | - | - | Stock Option (right to buy) | |
| Myriad Genetics, Inc. | Colleen F. Reitan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 15,151 | 72,850 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Colleen F. Reitan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 3,454 | 3,454 | - | - | Stock Option (right to buy) | |
| Myriad Genetics, Inc. | Colleen F. Reitan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 17,275 | 57,699 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Colleen F. Reitan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 5,153 | 5,153 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Colleen F. Reitan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2021 | 4,032 | 4,032 | - | - | Stock Option (right to buy) |